Publications by authors named "He-mai-jiang Ai"
[Expression Level and Target Gene Prediction of miR-181b in Patients with Chronic Lymphocytic Leukemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
June 2020
Objective: To investigate the expression level of miR-181b in CD19+ B lymphocytes of patients with chronic lymphocytic leukemia (CLL), to analyze the relationship between its expression and the prognosis of CLL patients, and to predict the potential target gene of miR-181b in CLL by using bioinformatics.
Methods: Eight-four patients with CLL treated in People's Hospital of Xinjiang Uygur Autonomous Region from June 2013 to June 2018 were selected. and 20 healthy people were selected as control group.
Article Synopsis
- - The study aimed to evaluate the effectiveness of a specific immune-stimulatory method (CpG-ODN DSP30+IL-2) in improving chromosome culture results for chronic lymphocytic leukemia (CLL) cells and to compare findings with other research.
- - Researchers used bone marrow samples from 82 CLL patients, comparing two stimulants: phytohemagglutinin (PHA) and CpG-ODN DSP30+IL-2; results showed a significantly higher success rate in karyotype culture for PHA while the CpG-ODN DSP30+IL-2 group had a higher detection of abnormal karyotypes.
- - The conclusion highlights that using the CpG-OD
[Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
Zhonghua Xue Ye Xue Za Zhi
March 2012
Objective: To investigate the efficacy and safety as well as the effects of lower dose of rituximab on B-lymphocytes, serum immunoglobulin, and platelet glycoprotein-specific antibodies in patients with chronic refractory immune thrombocytopenic purpura (ITP).
Methods: Twenty chronic refractory ITP patients, median age 47 (20 to 60) years old, received intravenous rituximab at the dose of 100mg once weekly for 4 consecutive weeks. Laboratory studies included complete blood cell count, regular monitoring of liver and kidney functions, blood coagulation and serum concentrations of IgG, IgM and IgA.